Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/58775
Type: Journal article
Title: Incretin-based therapies: New treatments for type 2 diabetes in the new millennium
Author: Khoo, J.
Rayner, C.
Jones, K.
Horowitz, M.
Citation: Therapeutics and Clinical Risk Management, 2009; 5(1):683-698
Publisher: Dove Medical Press Ltd.
Issue Date: 2009
ISSN: 1176-6336
1178-203X
Statement of
Responsibility: 
Joan Khoo, Christopher K Rayner, Karen L Jones, and Michael Horowitz
Abstract: The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term.
Keywords: incretin; type 2 diabetes; therapy; GLP‑1 DPP‑4
Rights: © 2009 Khoo et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
RMID: 0020096145
Published version: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731024/pdf/tcrm-5-683.pdf
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.